title: Molecular Adsorbent Recirculating System: clinical experience in patients with liver failure based on hepatitis B in China.
abstract: The aim of this study is to evaluate the effect of treatment with the Molecular Adsorbent Recirculating System (MARS) on liver failure based on HBV. In 25 patients (median age, 36.3 years, range, 22-67 years, bilirubin level > 255 micro mol/l) admitted with liver failure based on HBV, the 6-8h MARS intermittent treatments were performed without any adverse events, A significant decrease in bilirubin, ammonia and urea levels were observed (P < 0.05). All patients achieved a remarkable neurologic recovery, particularly 2 HE-III and 3 HE-IV patients regained normal consciousness, respectively. The survival rate for the patients whose treatments kept to the MARS art strategy was 76.9% (10/13), while the others only had the survival rate of 16.7% (2/12) due to their giving up sequential MARS treatments after the first time. The rebounding rate of the bilirubin level in the patients after a single MARS treatment was significantly lower than that of patients, who underwent a single plasma-exchange treatment (P < 0.01). It is concluded that MARS method can contribute to the optimistic treatment of liver failure patients based on HBV which being the major epidemic liver disease in China.
authors.affiliation: Department of Medicine, Jiangxi Medical College, P.R.China.
authors.forename: Shibin
authors.initials: S
authors.lastname: Chen
authors.forename: Lunli
authors.initials: L
authors.lastname: Zhang
authors.forename: Yufei
authors.initials: Y
authors.lastname: Shi
authors.forename: Xiaolan
authors.initials: X
authors.lastname: Yang
authors.forename: Minmin
authors.initials: M
authors.lastname: Wang
mesh_terms: D000641:Ammonia / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002681:China; D003404:Creatinine / Q000097:blood; D006454:Hemoglobins; D006501:Hepatic Encephalopathy / Q000097:blood / Q000401:mortality / Q000628:therapy; D006509:Hepatitis B / Q000097:blood / Q000401:mortality / Q000628:therapy*; D006801:Humans; D017093:Liver Failure / Q000097:blood / Q000401:mortality / Q000628:therapy*; D010951:Plasma Exchange; D010976:Platelet Count; D006435:Renal Dialysis; D012709:Serum Albumin; D016060:Sorption Detoxification; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins; D012709:Serum Albumin; D000641:Ammonia; D003404:Creatinine; D001663:Bilirubin